뒤로
Unicycive Therapeutics Inc(UNCY) 가격
UNCY 주가 차트
UNCY 수입
Unicycive Therapeutics Inc
$6.08
-2.71%
$-0.16
종가: Feb 12, 16:00:00 GMT-5
$6.08
0%
$0
프리마켓: Feb 13, 06:25:15 GMT-5
최신 수익 결과: Q3 '25
보고됨: 2025-11-12
역사적 수익
분기별
연간
EPS
수익
Earnings FAQ
UNCY의 최근 주당순이익(EPS)은 예상과 비교하여 어떤가요?
Unicycive Therapeutics Inc UNCY의 지난 분기 매출 실적은 어땠나요?
Unicycive Therapeutics Inc의 매출 추정치는 얼마인가요?
Unicycive Therapeutics Inc의 수익 품질 점수는 얼마인가요?
Unicycive Therapeutics Inc는 언제 수익을 보고하나요?
Unicycive Therapeutics Inc의 예상 수익은 얼마인가요?
Unicycive Therapeutics Inc은 수익 기대치를 충족했나요?
주요 통계
이전 종가
$6.25
시가
$6.28
일일 범위
$5.98 - $6.28
52주 범위
$3.71 - $11
거래량
303.6K
평균 거래량
500.7K
EPS(TTM)
-2.01
배당수익률
--
시가총액
$130.6M
UNCY란 무엇인가요?
Unicycive Therapeutics, Inc. engages in the development of treatment for kidney diseases. The company is headquartered in Los Altos, California and currently employs 22 full-time employees. The company went IPO on 2021-06-17. The firm's lead drug candidate, oxylanthanum carbonate (OLC), is an investigational phosphate binding agent being developed for the treatment of hyperphosphatemia in chronic kidney disease patients on dialysis. Its second asset, UNI-494, is a patent-protected new chemical entity in clinical development for the treatment of conditions related to acute kidney injury.